Electrochemiluminescent assay instruments offer increased sensitivity and
KING OF PRUSSIA, PA, June 2 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, now offers
its bioanalysis clients the benefits of electrochemiluminescent assay (ECLA)
testing, with the recent installation and validation of two state-of-the-art
instruments at its laboratory in Montreal.
In many situations, ECLA test methodology provides greater sensitivity
and flexibility than standard radioimmunoassays or ELISA techniques for
quantitative pharmacokinetic and immunogenicity testing of biological samples
from clinical research participants.
These advantages are particularly important in research involving
biologics such as monoclonal antibodies because traditional methodologies may
not be capable of detecting anti-drug antibodies in the presence of
circulating drug. Biologic drugs are made using living cells rather than
chemicals and therefore have the potential to trigger a potentially harmful
"With the growing focus on biologic drugs, including biologic generics,
the need to detect immune responses during clinical research becomes
increasingly important," said MDS Pharma Services President David Spaight.
"That's why MDS Pharma Services has added ECLA testing to our bioanalytical
testing repertoire of ligand binding and cell-based assays."
MDS Pharma Services is developing ECLA assays for bone and metabolic
biomarkers to leverage the instruments' multiplexing capabilities, which allow
for measurement of multiple analytes or markers in a single test sample. This
multiplexing ability offers clients increased productivity in keeping with MDS
Pharma Services' brand promise to deliver high-quality results on time.
To accelerate client access to the benefits of ECLA methodology, MDS
Pharma Services fast-tracked the validation of the two instruments and
associated software, redeploying resources to complete the validation process.
The instruments and software meet all applicable regulatory requirements,
including 21 CFR Part 11.
About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service on-time.
We offer a full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology industries. With
numerous facilities strategically located around the world, we apply advanced
scientific and technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research, early clinical
research (bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized cardiac
services. For more information, visit our website at www.mdsps.com.
MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ),
a global life sciences company that provides market-leading products and
services that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 5,500 highly skilled people in
28 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222,
24 hours a day.
For further information:
For further information: For Investors, Kim Lee, (416) 213-4721,
email@example.com; For Media, Charlene McGrady, (610) 239-7900 ext. 231,